Study real-world outcomes of IBD infliximab patients with the Anser TDM Test: Presentation by Prometheus using the Lynx GI data library
PALO ALTO, CA / ACCESSWIRE / January 17, 2024 / Lynx.MD, a provider of a comprehensive medical data intelligence platform, is honored to support our partner, Andrew Shim, Medical Affairs, Prometheus Laboratories Inc, poster presentation at the upcoming Crohn’s & Colitis Congress 2024 demonstrating the potential of therapeutic drug monitoring (TDM) to positively impact patient outcome with infliximab dose optimization.
Poster Session: Comparing Real-World Outcomes… Using TDM vs. Unoptimized Control Group
Presenter: Dr. Andrew Shim, Prometheus Laboratories Inc., University of Minnesota
When: Friday, January 26th, 7:00 PM – 8:00 PM Pacific
Venue: Bellagio, Las Vegas
Key points of interest:
This study was made possible through a powerful collaboration between Prometheus Laboratories Inc. and Lynx.MD, a leading real-world medical data platform. Leveraging Lynx.MD’s rich repository of de-identified clinical data within the Lynx.MD Trusted Data Environment, Prometheus researchers gained unparalleled access to real-world treatment patterns and outcomes in a diverse patient population. This unique partnership exemplifies the power of data-driven research in advancing personalized medicine and ultimately improving patient lives.
Don’t miss this opportunity to learn more about this potentially transformative approach to IBD care at the Crohn’s & Colitis Congress. Attend Dr. Shim’s presentation to discover how data-driven insights can inform IBD treatments.
Additional Information:
Contact:
Victoria Holl
Vp of Marketing
Lynx.MD
victoria@lynx.md
650-248-4262
SOURCE: Lynx MD
View the original press release on accesswire.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…